AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36480510 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (30 seconds at 2 mA, 19 minutes at 0 mA) for 10 daily sessions plus 5 follow up sessions
Number of subjects: 50
Study 36480510 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 50
Study 36480510 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 50
Study 33221862 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Schools, Healthy Students (HSHS) intervention including education sessions, cafeteria coaching, and taste testing
Number of subjects: 1057
Study 33221862 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Schools, Healthy Students (HSHS)
Number of subjects: 1057
Study 33121256 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk odor
Number of subjects: 84
Study 33121256 — intervention group
Group type: COMPARATOR
Intervention: Formula milk odor
Number of subjects: 84
Study 35149568 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving three individual counselling sessions on CIH within 3 months
Number of subjects: 1500
Study 35149568 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving treatment as usual, no CIH counselling
Number of subjects: 1500
Study 35149568 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1500
Study 34296283 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Number of subjects: 0
Study 34296283 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab, pertuzumab and docetaxel
Number of subjects: 0
Study 35488270 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative e-Writing Intervention (NeW-I)
Number of subjects: 26
Study 35488270 — intervention group
Group type: EXPERIMENTAL
Intervention: NeW-I
Number of subjects: 26
Study 34459842 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended collaborative care for HF and depression (12 months)
Number of subjects: 756
Study 34459842 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 756
Study 34459842 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (eUC)
Number of subjects: 756
Study 34034627 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest algorithm for predicting problem coping experiences (PCE) effects in cognitive-behavioral therapy
Number of subjects: 1010
Study 32564661 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 78
Study 32564661 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 78
Study 32564661 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study 34321058 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate tapering of opioids
Number of subjects: 140
Study 34321058 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 140
Study 32440730 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin-type fructans (16 g)
Number of subjects: 25
Study 32440730 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 16 g)
Number of subjects: 25
Study 35658725 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 70
Study 35658725 — intervention group
Group type: COMPARATOR
Intervention: Brachial Plexus Block (BP)
Number of subjects: 70
Study 34344029 — intervention group
Group type: EXPERIMENTAL
Intervention: Givosiran (monthly subcutaneous injection)
Number of subjects: 0
Study 32711554 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose platinum-based chemotherapy
Number of subjects: 114
Study 32711554 — intervention group
Group type: COMPARATOR
Intervention: Non-BRCA-like patients
Number of subjects: 114
Study 35089960 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2g/day)
Number of subjects: 58
Study 35089960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 35089960 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and Placebo (PCOS mothers)
Number of subjects: 58
Study 35089960 — intervention group
Group type: COMPARATOR
Intervention: Low-risk reference population
Number of subjects: 58
Study 33650197 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan, 25 mg, twice a day
Number of subjects: 80
Study 33650197 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine, 5 mg per day
Number of subjects: 80
Study 32221052 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy
Number of subjects: 108
Study 32221052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 36199257 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training bout
Number of subjects: 30
Study 36199257 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 30
Study 33096006 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (interval, continuous, combination) for 3 months
Number of subjects: 83
Study 33096006 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 83
Study 32229466 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Video (NV)
Number of subjects: 22
Study 32229466 — intervention group
Group type: COMPARATOR
Intervention: Non-Narrative Video (NNV)
Number of subjects: 22
Study 36415996 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 20 minutes, 20 sessions over 4 weeks)
Number of subjects: 28
Study 36415996 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study 32033152 — intervention group
Group type: EXPERIMENTAL
Intervention: High consumption of lactose-rich foods
Number of subjects: 52
Study 32033152 — intervention group
Group type: EXPERIMENTAL
Intervention: High consumption of other FODMAP-rich foods
Number of subjects: 52
Study 32033152 — intervention group
Group type: EXPERIMENTAL
Intervention: High consumption of both lactose-rich and other FODMAP-rich foods
Number of subjects: 52
Study 33771716 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole coadministration (Period II)
Number of subjects: 0
Study 33771716 — intervention group
Group type: COMPARATOR
Intervention: Control (Period I, no itraconazole)
Number of subjects: 0
Study 32281817 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory control training (ICT)
Number of subjects: 60
Study 32281817 — intervention group
Group type: COMPARATOR
Intervention: Control/sham training
Number of subjects: 60
Study 35247167 — intervention group
Group type: EXPERIMENTAL
Intervention: Stability-based training with visualisation (VIS) for 4 weeks
Number of subjects: 17
Study 35247167 — intervention group
Group type: COMPARATOR
Intervention: Stability-based training without visualisation (NO-VIS) for 4 weeks
Number of subjects: 17
Study 32975161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral catheter treatment
Number of subjects: 6459
Study 32975161 — intervention group
Group type: COMPARATOR
Intervention: Control group (no APN)
Number of subjects: 6459
Study 32375605 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG group (IC-ECG method)
Number of subjects: 2250
Study 32375605 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional landmark length estimation)
Number of subjects: 2250
Study 32375605 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2250
Study 32375605 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG group
Number of subjects: 2250
Study 35988167 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP‐EPI (1 mL subcutaneously injected 1 day before surgery)
Number of subjects: 60
Study 35988167 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 60
Study 34507350 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 128
Study 34507350 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice (methotrexate or bexarotene)
Number of subjects: 128
Study 34252556 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteochondroplasty
Number of subjects: 0
Study 34252556 — intervention group
Group type: COMPARATOR
Intervention: Lavage (control group)
Number of subjects: 0
Study 34252556 — intervention group
Group type: COMPARATOR
Intervention: Osteochondroplasty (RCT group)
Number of subjects: 0
Study 34252267 — intervention group
Group type: EXPERIMENTAL
Intervention: Horyzons online therapy
Number of subjects: 12
Study 34706047 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (15 minutes) plus swaddling
Number of subjects: 52
Study 34706047 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (10 minutes) plus swaddling
Number of subjects: 52
Study 34706047 — intervention group
Group type: COMPARATOR
Intervention: No music (10 minutes) plus swaddling
Number of subjects: 52
Study 34706047 — intervention group
Group type: COMPARATOR
Intervention: No music (15 minutes) plus swaddling
Number of subjects: 52
Study 32374527 — intervention group
Group type: COMPARATOR
Intervention: IBWL (Internet-Based Weight Loss)
Number of subjects: 180
Study 32374527 — intervention group
Group type: EXPERIMENTAL
Intervention: IBWL + $ (Internet-Based Weight Loss with Financial Incentives)
Number of subjects: 180
Study 33098434 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/day)
Number of subjects: 1312
Study 33098434 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1 g/day)
Number of subjects: 1312
Study 33098434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1312
Study 35578253 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (n = 176) evaluated with exploratory factor analysis
Number of subjects: 352
Study 35578253 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (n = 176) evaluated with confirmatory factor analysis
Number of subjects: 352
Study 35578253 — intervention group
Group type: COMPARATOR
Intervention: Participants performing traditional menstrual practices
Number of subjects: 352
Study 35578253 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative menstrual attitudes
Number of subjects: 352
Study 616407122 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rehabilitation exercise program and prolotherapy (EPG)
Number of subjects: 30
Study 616407122 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercise program alone (EG)
Number of subjects: 30
Study 616407122 — intervention group
Group type: COMPARATOR
Intervention: Prolotherapy alone (PG)
Number of subjects: 30
Study 34775857 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education and counseling intervention
Number of subjects: 235
Study 34775857 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutrition education and counseling)
Number of subjects: 235
Study 32869361 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of poultry
Number of subjects: 986
Study 32869361 — intervention group
Group type: COMPARATOR
Intervention: No poultry consumption (Control)
Number of subjects: 986
Study 32869361 — intervention group
Group type: COMPARATOR
Intervention: Consumption of pork, beef, lamb, processed meat, total meat
Number of subjects: 986
Study 32468765 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic pre-operative antibiotics
Number of subjects: 121
Study 32468765 — intervention group
Group type: COMPARATOR
Intervention: No pre-operative antibiotics
Number of subjects: 121
Study 36443769 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (Group-A)
Number of subjects: 244
Study 36443769 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Group-B)
Number of subjects: 244
Study 33782684 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt substitute (70% sodium chloride/30% potassium chloride blend)
Number of subjects: 502
Study 33782684 — intervention group
Group type: COMPARATOR
Intervention: Regular salt (100% sodium chloride)
Number of subjects: 502
Study 32043808 — intervention group
Group type: EXPERIMENTAL
Intervention: Zheng's Supine Rehabilitation Exercise (ZSRE)
Number of subjects: 82
Study 35939865 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lacticaseibacillus paracasei SD1, L. rhamnosus SD4, L. rhamnosus SD11, Limosilactobacillus fermentum SD7)
Number of subjects: 20
Study 35939865 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 20
Study 34276009 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (canagliflozin 100 mg/day or dapagliflozin 5 mg/day or empagliflozin 10 mg/day)
Number of subjects: 81
Study 34276009 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 81
Study 32621449 — intervention group
Group type: EXPERIMENTAL
Intervention: Razi vaccine
Number of subjects: 14250
Study 32621449 — intervention group
Group type: EXPERIMENTAL
Intervention: Dn vaccine
Number of subjects: 14250
Study 32621449 — intervention group
Group type: EXPERIMENTAL
Intervention: Vc vaccine
Number of subjects: 14250
Study 32621449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ch vaccine
Number of subjects: 14250
Study 35652323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI) involving cognitive behavioral therapy (CBT)
Number of subjects: 183
Study 35652323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI) involving CBT with additional short message service (SMS)
Number of subjects: 183
Study 35652323 — intervention group
Group type: COMPARATOR
Intervention: Control (care as usual [CAU])
Number of subjects: 183
Study 35652323 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline weight
Number of subjects: 183
Study 35652323 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of androstenedione
Number of subjects: 183
Study 35652323 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher depression scores
Number of subjects: 183
Study 33905962 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus erlotinib (RAM + ERL)
Number of subjects: 113
Study 33905962 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus erlotinib (PBO + ERL)
Number of subjects: 113
Study 35218191 — intervention group
Group type: COMPARATOR
Intervention: l-methionine (reference diet) at 0.5, 1, 2, and 3 mg.kg-1.d-1
Number of subjects: 5
Study 35218191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked lentils + rice (test diets)
Number of subjects: 5
Study 33397427 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose heparinization aiming for an activated clotting time (ACT) of 140–180 s
Number of subjects: 218
Study 33397427 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparinization aiming for a partial thromboplastin time (PTT) of 35–40 s
Number of subjects: 218
Study 35367069 — intervention group
Group type: EXPERIMENTAL
Intervention: fIPV-dmLT
Number of subjects: 29
Study 35367069 — intervention group
Group type: COMPARATOR
Intervention: fIPV
Number of subjects: 29
Study 33548518 — intervention group
Group type: EXPERIMENTAL
Intervention: Tree SLIT-tablet (12 SQ-Bet)
Number of subjects: 634
Study 33548518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 634
Study 36064525 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-proxied beta-blocker (BB)
Number of subjects: 4743
Study 36064525 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-proxied calcium channel blocker (CCB)
Number of subjects: 4743
Study 33370444 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedded athletic training musculoskeletal care model (2 certified athletic trainers and a sports medicine fellowship‐trained physician)
Number of subjects: 0
Study 36404525 — intervention group
Group type: EXPERIMENTAL
Intervention: Futibatinib 20 mg
Number of subjects: 48
Study 36404525 — intervention group
Group type: EXPERIMENTAL
Intervention: Futibatinib 80 mg
Number of subjects: 48
Study 36404525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 36404525 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 48
Study 33565691 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg once-daily)
Number of subjects: 61
Study 33565691 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100 mg once-daily)
Number of subjects: 61
Study 32653447 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744
Study 32653447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study 36179323 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient Events (TEs; less than 60 seconds)
Number of subjects: 1100
Study 36179323 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Events (PEs; 60 seconds or longer)
Number of subjects: 1100
Study 36179323 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Events (PEs) during nursing shift 2 (3 pm to 11 pm)
Number of subjects: 1100
Study 36179323 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of TEs within PEs
Number of subjects: 1100
Study 36179323 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity levels during nursing shifts
Number of subjects: 1100
Study 35583344 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (RIF) added to DRV/r 800/100 mg once daily (QD) and then DRV/r 800/100 twice daily (BD) and 1,600/200 QD
Number of subjects: 17
Study 35583344 — intervention group
Group type: COMPARATOR
Intervention: DRV/r 800/100 mg once daily (QD)
Number of subjects: 17
Study 35583344 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin (RIF)
Number of subjects: 17
Study 33191251 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive hypotension (vasopressor titration to achieve MAP 60-65 mm Hg)
Number of subjects: 7
Study 33191251 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7
Study 33689654 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment videogame
Number of subjects: 105
Study 33689654 — intervention group
Group type: COMPARATOR
Intervention: Placebo videogame
Number of subjects: 105
Study 35278698 — intervention group
Group type: EXPERIMENTAL
Intervention: Provided vegetable intervention
Number of subjects: 51
Study 32996027 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS with self-care guidelines for managing side effects
Number of subjects: 0
Study 32996027 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS intervention)
Number of subjects: 0
Study 32353079 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss maintenance intervention
Number of subjects: 1421
Study 34562610 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg, Q3W) plus ipilimumab (3 mg/kg, Q3W) followed by nivolumab monotherapy (240 mg, Q2W) for up to 12 months
Number of subjects: 153
Study 34562610 — intervention group
Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 153
Study 33002868 — intervention group
Group type: EXPERIMENTAL
Intervention: Subperiosteal drain (SPD)
Number of subjects: 104
Study 33002868 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdural drain (SDD)
Number of subjects: 104
Study 36267318 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotrend (NT) group (supervised anesthesia under NT monitoring)
Number of subjects: 144
Study 36267318 — intervention group
Group type: COMPARATOR
Intervention: Control group (anesthesia according to doctors' experience)
Number of subjects: 144
Study 34453234 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir (1800 mg twice a day on Day 1, followed by 800 mg twice a day for up to 13 days)
Number of subjects: 156
Study 34453234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 34453234 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 156
Study 34049120 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive 3D interactive video program
Number of subjects: 45
Study 34049120 — intervention group
Group type: COMPARATOR
Intervention: Regular demonstration video
Number of subjects: 45
Study 33416742 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician + patient intervention
Number of subjects: 538
Study 33416742 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician‐only intervention
Number of subjects: 538
Study 33416742 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 538
Study 36374742 — intervention group
Group type: EXPERIMENTAL
Intervention: drug-laser-photon therapy
Number of subjects: 75
Study 36254422 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 25 mcg
Number of subjects: 150
Study 36254422 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 50 mcg
Number of subjects: 150
Study 36254422 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 75 mcg
Number of subjects: 150
Study 36254422 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 100 mcg
Number of subjects: 150
Study 36254422 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (Control)
Number of subjects: 150
Study 33883768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8mg (2mls of 4mg/ml)
Number of subjects: 94
Study 33883768 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2mls of saline)
Number of subjects: 94
Study 33358704 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine
Number of subjects: 95
Study 33358704 — intervention group
Group type: COMPARATOR
Intervention: Comparator vaccine
Number of subjects: 95
Study 33021328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered early, <3h post-injury
Number of subjects: 12737
Study 33021328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12737
Study 35129000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent kangaroo care for 30 minutes once a day for 10 days
Number of subjects: 60
Study 35129000 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 34037993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 3716
Study 32635281 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic Ai Chi therapy
Number of subjects: 45
Study 32635281 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (alternating sessions of physiotherapy on dry land and aquatic Ai Chi therapy)
Number of subjects: 45
Study 32635281 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy treatment on dry land (control group)
Number of subjects: 45
Study 34930688 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention strategy (exercise, diet, peer education)
Number of subjects: 2005